Moneycontrol PRO

Buy Aarti Drugs; target of Rs 844: Anand Rathi

Anand Rathi is bullish on Aarti Drugs has recommended buy rating on the stock with a target price of Rs 844 in its research report dated July 28, 2021.

August 04, 2021 / 04:37 PM IST
An Edelweiss research report for Q4FY21 says road tonnage continued to improve, evident in e-way bill generation (up 6% QoQ) and improved core trucking rentals. “We estimate tonnage would increase by three–five percent for truckers. Asset-light plays Mahindra Logistics and TCI Express remain our preferred picks due to their ability to scale up/down as the environment demands,” the report said. Edelweiss is bullish on Blue Dart Express due to the pandemic-induced boom in e-commerce and its leaner cost structure. It has retained a ‘buy’ call on Mahindra Logistics, TCI Express and Blue Dart Express.

An Edelweiss research report for Q4FY21 says road tonnage continued to improve, evident in e-way bill generation (up 6% QoQ) and improved core trucking rentals. “We estimate tonnage would increase by three–five percent for truckers. Asset-light plays Mahindra Logistics and TCI Express remain our preferred picks due to their ability to scale up/down as the environment demands,” the report said. Edelweiss is bullish on Blue Dart Express due to the pandemic-induced boom in e-commerce and its leaner cost structure. It has retained a ‘buy’ call on Mahindra Logistics, TCI Express and Blue Dart Express.

 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Anand Rathi's research report on Aarti Drugs


Raw-material price rises and a higher share of domestic sales dented Aarti’s gross margin 966bps to 31.7%. Certain maintenance costs pulled down the EBITDA margin more, to 1,085bps. Revenue grew 6.5% to Rs5.8bn on 6.7% growth in formulations, and 38.5% in specialty chemicals. API sales were up 3.9% to Rs4.5bn. Via better utilisation of capacities and addition of products, Aarti is on track for 18% revenue growth in the next 4-5 years. We cut our FY22e/FY23e EPS 18.6%/11.1% to factor in the temporary rise in raw-material prices.



Outlook


We retain our Buy rating and lower our target to Rs844 (earlier Rs949) on 20x FY23e earnings.

Close

For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.

Broker Research
first published: Aug 4, 2021 04:37 pm

stay updated

Get Daily News on your Browser
Sections
ISO 27001 - BSI Assurance Mark